FORMULATION AND EVALUATION OF MODIFIED ORAL CHRONOTROPIC DRUG DELIVERY SYSTEMS OF TRAMADOL HYDROCHLORIDE FOR RHEUMATOID ARTHRITIS PAIN
Objective: The main aim was to develop a modified oral chronotropic system for timed release tramadol hydrochloride (tramadol HCl). Biological rhythms are highly organized for all functions of the human body both in health and in disease. Hence, drug delivery systems were designed to make possible the treatment of illness based on biological rhythms for improving therapeutic efficacy.
Materials and Methods: These systems consist of immediate release core tablet of tramadol HCl using different materials such as SSG, crospovidone, pregelatinized starch and then coated with Tamarindus gum, hydroxypropyl methylcellulose (HPMC), and their combination. This coated tablet is enteric coated with Eudragit L 100, Eudragit S100 to produce lag time period of 5 h.
Results: Immediate release systems are optimized with formulation F6 containing pregelatinized starch as an immediate release agent, the formulation is coated with Tamarindus gum, HPMC, and their combination. The release retardant behavior of Tamarindus gum was evaluated in compressed coated formulations. This coated tablet is enteric coated with Eudragit L 100, Eudragit S100 to release the drug after the lag time period of 5 h.
Conclusion: A modified oral chronotropic system for timed release of tramadol HCl was made possible with the compressed coated tablets CF3 which shows better drug release followed by enteric coating with Es c coat fulfilled our objective of work.
2. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012;7:e30275.
3. Hinz B, Brune K. Antipyretic analgesics: Nonsteroidal antiinflammatory drugs, selective COX-2 inhibitors, paracetamol and pyrazolinones. Handb Exp Pharmacol 2007;15:65-93.
4. Ziegler CM, Wiechnik J, Mühling J. Analgesic effects of intra-articular morphine in patients with temporomandibular joint disorders: A prospective, double-blind, placebo-controlled clinical trial. J Oral Maxillofac Surg 2010;68:622-7.
5. Lang LJ, Pierer M, Stein C, Baerwald C. Opioids in rheumatic diseases. Ann N Y Acad Sci 2010;1193:111-6.
6. Michael PL. Chronobiology and Chronotherapeutics-Possible Strategy for Hypertension and Ischemic Heart Disease 2009;6:112-6. Available from: http://www.touchcardiology. Com/articles/chronobiology-and-chronotherapeutics-possible-strategy-hypertension-and-ischemic-heart disease.
7. Neeharika MS, Jeevanajyothi B. Chronotherapeutics: An optimizing approach to synchronize drug delivery with circadian rhythm. J Crit Rev 2015;2 4 Suppl 1:31-40.
8. Rahman S, Al Masum A, Sharmin F, Islam SM, Reza M. Formulation and evaluation of bi-layered sustained release matrix tablets of tramadol hydrochloride. J Appl Pharm Sci 2012;2:129-34.
9. Panchal LA, Shelat PK, Zaveri MN. Development of sustained release matrix tablet of tramadol hydrochloride using natural gums. Int J Pharm Pharm Sci 2012;4 1 Suppl 4:153-7.
10. Kushwaha P, Fareed S, Nanda S, Mishra A. Design and fabrication of tramadol HCl loaded multiparticulate colon targeted drug delivery system. J Chem Pharm Res 2011;3:584-95.
11. Gowthamarajan K, Kulkarni GT, Kumar AM, Mahadevan N, Samantha MK, Suresh B, et al. Evaluation of binding properties of Plantago ovata and Trigonella foenum-graecum mucilages. Int J Pharm Excip 2002;4:16-9.
12. Malviya R, Srivastava P, Bansal M, Sharma PK. Formulation, evaluation, and comparison of sustained release matrix tablets of diclofenac sodium using tamarind gum as release modifier. Asian J Pharm Clin Res 2010;3:238-41.
13. Patel H, Pandey S, Patel V, Shah R, Tiwari S. Pulsatile release of ketoprofen from compression coated tablets using eudragit® polymers. Int J Pharm Pharm Sci 2016;8:224-9.
14. Omidian H, Park K, Qiu Y, Yang S, Kim D. Swelling agents and devices in oral drug delivery. J Drug Deliv Sci Technol 2008;18:83-93.
15. Abhinetri V, Hadi MA, Rao AS, Sravani V. Development of a novel enteric coated extended release pellets using model NSAID flurbiprofen. Int J Pharm Sci Res 2013;4:754-60.
16. Chikkanna N, Mayasandra SS. Study the effect of formulation variables in the development of timed-release press-coated tablets by Taguchi design. Nat Sci 2010;2:379-87.
17. Keith M. Compression and consolidation of the powdered solids. In: Leon Lachman, Liberman HA, Kanig JL, editors. Theory and Practice of Industrial Pharmacy. 3rd ed. Mumbai, India: Varghese Publishing House; 1991. p. 66-72.
18. The United States Pharmacopoeial Convention. USP NF, The Official Compendia of Standards. National Formulary. 30th ed. Rockville, Md: United States Pharmacopeial Convention; 2007. p. 1567.
19. Gazzaniga A, Palugan L, Foppoli A, Sangalli ME. Oral pulsatile delivery systems based on swellable hydrophilic polymers. Eur J Pharm Biopharm 2008;68:11-8.
20. Kim IH, Park JH, Cheong IW, Kim JH. Swelling and drug release behavior of tablets coated with aqueous hydroxypropyl methylcellulose phthalate (HPMCP) nanoparticles. J Control Release 2003;89:225-33.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.